US Surgical's Alliance Strategy
Well, US Surgical is back. While still nowhere near its historic highs, its stock rose nearly 100% last year. And a series of alliances the company has done recently shows this technology-driven company is as hungry as ever.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.